Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Scott Kirkland
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> - Controller of Trustee and beneficiary of trust
Date of change	27 November 2026
No. of securities held prior to change	Mr Scott Philip Kirkland 3,861,987 ordinary shares (EMV) KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> 415,000 total ordinary shares (EMV)
Class	Performance Rights & Unlisted options
Number acquired	800,000 Performance Rights & 400,000 Unlisted options
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Valuation information as set out in the 2026 AGM Notice of Meeting
No. of securities held after change	Mr Scott Philip Kirkland 3,861,987 ordinary shares (EMV) 800,000 performance rights, expiry date 30 June 2031 200,000 unlisted options, exercise price $2.40, expiry date 30 June 2030 200,000 unlisted options, exercise price $2.70, expiry date 30 June 2031 KIRKLAND CAPITAL PTY LTD <THRILL FURKHAND A/C> 415,000 total ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at 2026 AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMVision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr John Keep
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JOHN KEEP & SONS PTY LTD – Controller of company GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> - Controller of trustee and beneficiary of trust
Date of change	27 November 2026
No. of securities held prior to change	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV) GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> 1,112,000 ordinary shares (EMV) JOHN KEEP 347,170 ordinary shares (EMV)
Class	Unlisted options
Number acquired	300,000

+ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Valuation information as set out in the 2026 AGM Notice of Meeting
No. of securities held after change	JOHN KEEP & SONS PTY LTD 607,500 ordinary shares (EMV) GLENSBURG PTY LTD <TYTO CORPORATION PENSION FUND A/C> 1,112,000 ordinary shares (EMV) 300,000 unlisted options, exercise price $2.70, expiry date 30 June 2031 JOHN KEEP 347,170 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at 2026 AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philip Dubois
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	BONATA PTY LTD <AZTEC INVESTMENT A/C> - Controller of trustee and beneficiary of trust ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> - Controller of trustee and beneficiary of super fund
Date of change	27 November 2026
No. of securities held prior to change	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV) ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV)
Class	Unlisted options

+ See chapter 19 for defined terms.

Number acquired	200,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Valuation information as set out in the 2026 AGM Notice of Meeting
No. of securities held after change	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV) ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV) 200,000 unlisted options, exercise price $2.70, expiry date 30 June 2031
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at 2026 AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Tony Keane
Date of last notice	2 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> - Trustee and beneficiary of trust
Date of change	27 November 2026
No. of securities held prior to change	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV) PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> 500,000 ordinary shares (EMV)
Class	Unlisted options
Number acquired	200,000
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Valuation information as set out in the 2026 AGM Notice of Meeting
No. of securities held after change	MR ANTHONY GERARD KEANE 100,000 ordinary shares (EMV) 200,000 unlisted options, exercise price $2.70, expiry date 30 June 2031 PATRICIA KERRY KEANE & ANTHONY GERARD KEANE <THE KEANE FAMILY A/C> 500,000 ordinary shares (EMV)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities approved at 2026 AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.